We are pleased to announce that Alan Knox has been appointed as the new Managing Director of the Colonis Pharma business.
Alan brings with him over 40 years of experience, having worked in both large pharmaceutical businesses and across the generics industry.
The appointment comes at a crucial time for Colonis with the retirement of former managing director Andrew Trouton, who led a strategic focus on local and international expansion.
Andy originally joined the Colonis business as Managing Director in 2018 before being promoted to Senior Director of the Products division at Clinigen. Andy rejoined the Colonis Pharma business in April 2023 as a consultant to support the transition of the business back to a stand-alone operation within the Clinigen Group.
Alan’s previous career roles include CEO of Primex Pharmaceuticals, Vice President Global Portfolio Strategy Lead at MSD, in addition to various positions at AstraZeneca and Sandoz. Most recently he served as a Non-Executive Director as a Commercial member of the Novumgen Board. He holds a bachelor’s degree in Biomolecular Science from Portsmouth University.
Alan commented on his appointment: “It’s a privilege to join Colonis at such a pivotal time, driving innovation in the world of value-added medicines. We want to strengthen our already proven business model, keeping a clear commercial strategy towards success and growth that ultimately benefits patients.”
Please join us in welcoming Alan to the Colonis Pharma and Clinigen teams, and in wishing Andy a well-deserved retirement.
To find out more about our team, click here.
GB-CPL-0-296
June 2025
